Summary. The insulin response of isolated islet cells to glucose and theophylline in vitro was studied after incubation with lymphocytes. The test was employed to explore cell-mediated immunity in diabetics. A significant inhibition of insulin response to glucose and theophylline as compared to insulin release in a "basal" medium was found after incubation with blood lymphocytes from 21 out of 23 insulin-dependent diabetics (mean secretion index 18 ± 8 versus 118 ± 8 (SEM) % in control subjects). Most of the patients studied had associated autoimmune diseases: all of these displayed inhibition of insulin release. In six cases, the diabetes had a recent onset with no associated autoimmune disease: four of them displayed the same inhibition. No inhibition was found in the 26 control subjects and in seven noninsulin-dependent diabetics (mean secretion index 134 ± 17 versus 145 ± 23 (SEM) % in four control subjects). Lymphocytes inhibiting islet cell response were not cytotoxic against mouse fibroblasts. Twenty-two insulin-dependent diabetics showed islet cell antibodies to human and/or mouse pancreatic islets.. However, an inhibition of insulin release was found with no detectable islet cell antibodies in one case, and the converse in two cases. Lymphocyte cytotoxicity to islet cells could play a role in the natural history of insulin-dependent diabetes.
tissue [3] . However, until recently [4, 5] , no evidence has been presented that ICA are actually cytotoxic for pancreatic cells. Similarly, there is no evidence that lymphocytes from IDD patients are cytotoxic against pancreatic cells, except in the special case of insulinoma cell culture [6] . The passive transfer of transient diabetes by circulating IDD lymphocytes has been described in one publication [7] , but this has not been confirmed by others [8] [9] [10] [11] .
In order to study cellular immunity in diabetics, a series of cases among whom many patients had associated autoimmune manifestations were studied. Blood lymphocytes from diabetic and control subjects were incubated in vitro in the presence of insulin-secreting mouse islet cells which were then submitted to a functional test based on B-cell stimulation by glucose and theophylline [12] . The presence of ICA was simultaneously investigated in the corresponding sera by indirect immuno-fluorescence. (Table 1) Twenty-three patients with IDD were studied. All were on insulin, the duration of treatment varying from two days (patients 2 and 10) to several years. As frequently observed in IDD, several patients had associated autoimmune manifestations. In fact, we purposely selected a large proportion of such patients: diabetes was associated with vitiligo in eight cases, thyroid disease in seven, and pernicious anaemia in two. In six other patients, the apparent onset of diabetes was recent (8-90 days before the study). Control subjects were 26 normal blood donors. Lymphocytes from seven non-insulin-dependent diabetics (NIDD) were also studied.
Subjects and Methods

Subjects
Lymphocytes
In all subjects lymphocytes were processed immediately after blood sampling. A lymphocyte-rich preparation was obtained from 15 m! blood using a Ficoll-Hypaquedensity gradient. Cells were then washed twice with Hanks' buffer and suspended in Minima! 00I2-186X/811002110041/$Ol.20 Essential Medium (MEM Eagle, Flow Laboratories, Rockville, Maryland), modified as described below (pH 7.4) to a final concentration of 4.10 6 Iymphocytes/m!.
Islet Cells
Pancreatic islets were isolated from DBA/2 adult female mice (CNRS, Orleans, France) as described by Lacy [13] . In each experiment, five pancreases were minced and treated with 15 mg collagenase (150 mU/mg), (Boehringer, Mannheim, FRG) in 3 ml of calcium-free, magnesium-free balanced salt solution (CMF) containing 15% fetal calf serum (pH 7.4). Islets were isolated by vigourous shaking at 30°C for 4-7 min, depending on collagenase activity, and 300-600 islets were picked out manually under a dissecting microscope and transferred to Petri dishes set on ice. Islets were then incubated with 5 ml EDTA (40 mg/ 100 ml CMF) at room temperature for 5 min, centrifuged (100 xg) for 1 min, transferred into a flask containing 60 mg Dispase (Boehringer, Mannheim, FRG) in 5 ml CMF and submitted to gentle mechanical shaking (80 strokes/min) at 37°C for 15 min [14] . The islet cell-containing supernatant was collected and the sediment was submitted to another 15-min treatment by Dispase, followed by a second supernatant collection. MEM (2 mi), supplemented with 10% fetal calf serum was added immediately to each supernatant. The supernatants were pooled, centrifuged (100 xg), washed twice The cell suspension was kept for 18 h at 37°C in MEM supplemented with 10% fetal calf serum, glutamine 2 mmol/l, sodium pyruvate 1 mmoill, non-essential amino-acids 0.814 mg/I, streptomycin 100 f.lg/ml and penicillin 100 !-tU/m!. This "basal" medium, containing 5.5 mmol/I glucose, was equilibrated with CO 2 /air (5%-95%). Final pH was 7.4; osmolarity 290 mosm/!.
Islet Cell Stimulation
The islet cell suspension was distributed into Falcon microtest plates (Becton-Dickinson, Oxnard, California; Microtest II; 5.10 3 cells/well in 0.1 mi), with the addition of either lymphocytes (4.10 5 /well in 0.1 mi) or basal medium (0.1 ml). Plates were centrifuged (100 xg for 3 min) in order to secure a tight cell-to-cell contact at the bottom of the wells, and then kept for an 18 h incubation period. At the end of the incubation, the wells were carefully washed, the supernatants collected for assessment of the pre-stimulatory insulin release, and replaced by "basal" or "stimulatory" medium. The "stimulatory" medium (osmolarity 305 mosm/I) consisted of supplemented MEM containing 16.5 mmol/l glucose and 5 mml/I theophylline (Sigma, St. Louis). The stimulatory influences of 16.5 mmoill glucose alone and 0.1 mg/ml gliclazide (Servier, France) were also tested. In some experiments, 10 f.lg/ml noradrenaline was added. In other instances, islet cells were preincubated with streptozotocin (Upjohn, Kalamazoo, Michigan; 1.5 mg/ml) for 3 or 18 h.
Five minutes after adding the "basal" or "stimulatory" medium, supernatants were collected and rapidly frozen for insulin determinations. Preliminary experiments had demonstrated that this 5-min interval was the optimal time for both maximal stimulatory effect and minimal destruction of insulin. In each experiment, the same batch of islet cells served for control and test incubations (in the absence and the presence of control and diabetic lymphocytes) in basal and stimulated conditions. All experiments were performed in sextuplicate.
Insulin was determined by radioimmunoassay [15] using charcoal for the separation of free and bound hormone, purified rat insulin as a standard, porcine 125 1 insulin as a tracer (CNTS, Paris, France), and a guinea pig antiporcine insulin antiserum (Dr. Kervran, Paris, France). The sensitivity of insulin assay was 6 f.lU/m!. The results were reproductible with a coefficient of variation of 10%.
Mouse Fibroblasts
To verify the absence of nonspecific cytotoxicity against non pancreatic cells, microcytotoxicity assays were performed against mouse fibroblasts [16, 17] . Seventeen-day-old mouse embryos were sacrificed to obtain a primary fibroblast monolayer. The fibroblast suspension, prepared by trypsinisation of the primary culture for 18 min at 37°C, was distributed into the wells of a microtest plate (100 cells/well) and incubated for 24 h at 37°C. The medium was discarded and replaced by the lymphocyte suspension as above. After a 48 h incubation, fibroblasts were stained with Crystal Violet and counted by visual examination. In all experiments, the influence of the lymphocyte suspension on the fibroblast culture was tested in a series of eight wells.
Organ-Specific Antibodies and Insulin Antibodies
Sera were tested for ICA using fresh postmortem human pancreas of blood group 0 kidney transplant donors [2] . Non-species-
Insulin Release in the Presence of Human Lymphocytes
Control Subjects (Table 2 Table 2 . Insulin release from mouse islet cells in the absence and presence of lymphocytes from control subjects or insulin-dependent diabetic patients
Results are mean values ± SEM of insulin release in experiments performed with 15 different batches of islet cells in both basal and stimulatory media (Methods Section). The insulin release was studied in the absence of lymphocytes and in the presence of lymphocytes from one or two control subjects or IDD patients in each experiment; n indicates the number of subjects studied in each group. Asterisks indicate a statistically significant difference between basal and stimulated release inside the same group (* p < 0.01, ** P < 0.001); § denote a statistically signifi- In order to compare the insulin release from different islet cell preparations, a secretion index was calculated: (Table 2) In IS different experiments the mean net basal release (in the presence of S.S mmol/l glucose) was S.O ± 1.0 ltU/S.103 cells/S min, and the mean net stimulated release (in the presence of 16.S mmol/l glucose and S mmol/l theophylline) was 11.4 ± 1.8 ltU/S.103 cells/S min (p < 0.001). The mean secretion index was 128% ranging from 66 to 306%. We compared the respective effect of various stimulatory or inhibitory media, in order to verify
Insulin Release in the Absence of Lymphocytes
Results
Control Studies with Fibroblasts:
Fibroblasts were counted at the end of the 48 h incubation period with diabetic lymphocytes and the result (mean number of fibroblasts ± SEM) was compared with that obtained in preparations incubated with controllymphocytes.
(net stimulated release) -(net basal release) Secretion index = x100 (net basal release)
Calculation and Expression of Results
specific ICA were sought on DBA/2 mouse pancreas. Classical immuno-fluorescence was performed on 5 fA.m sections of unfixed frozen tissue. All sera were first tested both undiluted and at a 'I, dilution, using fluorescent rabbit antihuman immunoglobulins (anti-IgG, IgA, IgM) and fluorescent antimouse IgG. Sera showing fluorescence on human pancreas sections were further studied with specific anti-IgG, anti-IgA and anti-IgM sera and titres were established with serial dilutions. Complement fixation was tested in a three layer technique using fresh normal human serum as a source of complement and anti-BlC serum. Fluorescent immunoglobulins were obtained from Dakopatts (Copenhagen). Sections of human adrenal and rat stomach were used for immuno-fluorescent detection of antibodies against gastric parietal cells and adrenal tissue. Thyroglobulin and thyroid microsomal antibodies were assessed with commercial haemagglutination kits (Welcome Reagents, Beckenham, England) and were considered positive when agglutination was observed at dilutions of 'III, and 'lilli"
respectively. All sera were tested for anti-insulin antibodies at a dilution of 1-10 according to Yalow and Berson [18] using 125 the same experiments (cases 1 and 8; secretion index 28 and 50%). In two cases (patients 2 and 6) lymphocytes did not suppress the B cell response to glucose and theophylline (secretion index 147 and 127%). In 17 of the 21 patients with inhibiting 1ym-phocytes, diabetes was associated with other autoimmune manifestations: vitiligo (cases 5, 7, 9, 12-14, 17-18), Hashimoto's thyroiditis (cases 3, 16 and 21), Graves' disease (cases 8 and 20), myxoedema (cases 11 and 19), and pernicious anaemia (cases 15 and 22) . The onset of diabetes was recent (within less than 90 days) in cases 1, 4, 10, and 23 (with inhibiting lymphocytes) and in cases 2 and 6 (without inhibiting lymphocytes). (Table 2) .
A significant B cell response to glucose and theophylline occurred in all experiments (Fig. 1) , and the secretion index was above 50% in all cases (mean value 115 ± 8%, range 54-204%).
Control Studies with Mouse Fibroblasts
Mouse fibroblasts were incubated. with lymphocytes from eight control subjects and four IDD patients whose lymphocytes were shown to suppress stimulated insulin release (cases 11, 15, 19 and 20) . No cytotoxicity was detected in any case.
Insulin-Dependent Diabetics:
In the presence of lymphocytes from IDD patients, the basal insulin release was 10.7 ± 1.1IlU/5.103 cells/5 min (n = 23), a value not significantly different from the corresponding result in the presence of control lymphocytes.
The mean stimulated insulin release of 12.3 ± 1.6IlU/5.103 cells/5 min (n = 23) was significantly lower than the corresponding release in the presence of control lymphocytes ( Table 2 ). The mean secretion index was 18 ± 8%, ranging from 0 to 147%. The heterogeneity of individual responses is illustrated in Fig. 1 : the insulin response to glucose and theophylline was suppressed by lymphocytes from 19 patients (cases 3-5, 7, 9-23; secretion index 0-26%). In two others, a B cell response occurred, but it was significantly lower than the response observed in the presence of control lymphocytes in
Organ-Specific Antibodies
Control Subjects: No ICA were detected in 24 of the 26 control subjects studied. Antibodies to human islets were present at a 1/4dilution in one subject. Antibodies to mouse islets were detected in the same subject and another control subject.
Insulin-Dependent Diabetics: ICA were detected in 20 patients using human pancreas. In all instances, antibodies were of the IgG class and complementfixing. Antibodies to mouse islet cells were present in 17 patients, three of whom were negative with human islets. Fourteen patients were positive for gastric parietal cells, and/or thyroid microsomes, and/or thyroglobulin antibodies. Anti~insulin antibodies + + were present in the serum from 10 of the 23 insulintreated patients; they were absent in the serum from the insulin-treated NIDD patients. (Table 3) ICA and cytotoxic lymphocytes were associated in most patients. In several cases, however, discordance was observed between the two tests. In the two patients whose lymphocytes did not display inhibition of the insulin stimulated release, ICA were present at high titres (cases 2 and 6). Conversely, lymphocytes displayed insulin suppression but sera were negative for antibodies to human islet cells in four patients (cases 9, 11, 12, 16) and to mouse islet cells in five (cases 3, 5-7, 14).
Comparison of Cellular and Humoral Immunity
Discussion
Autoimmune phenomena exist in some cases of IDD and possibly contribute to the destruction of pancreatic B cells. Several lines of evidence support this hypothesis: 1) insulitis is present in some recentonset diabetics [19, 20] [2, [22] [23] [24] . The significance of ICA may differ in these two types of IDD [2, 24] since they are transient in the former while they tend to persist at high titre in the latter. Islet cell antibodies and cell-surface binding antibodies [25] appear to be organ-specific but not species-specific; 5) finally, cell-mediated anti-islet immunity has been suggested on the basis of the leucocyte migration inhibition test [3, 26] . In a previous work [10] using dispersed islet cells in vitro, we observed that insulin release can be inhibited in mice by activated macrophages and by immune mouse lymphocytes. The present study suggests that Ficoll-separated lymphocytes from IDD patients suppress insulin release from mouse islet cells, particularly when these patients have autoimmune manifestations or recent-onset diabetes. It may be hypothesized that this phenomenon reflects an anti-insulin immunity resulting from insulin treatment rather than an immunity against B cells. However, inhibitory lymphocytes and ICA were present in two IDD patients treated with insulin for 2 days (cases 4 and 23), while they were absent in one NIDD patient who had received insulin for 4 month, 2 years before the test. Moreover, 12 patients with inhibitory lymphocytes had no detectable anti-insulin antibodies.
No cytotoxicity against fibroblasts was detected. This finding is consistent with an in vitro organspecific cell-mediated cytotoxicity against the islets. The lymphocytes from three patients which suppressed insulin release in vitro, did not suppress the basal and arginine stimulated glucagon release from dispersed islet cells (unpublished observations), a result consistent with a selective B cell inhibition.
Although most of the IDD patients displayed serum ICA, as demonstrated by immunofluorescence techniques using human or mouse pancreas, no constant correlation was found between the presence of inhibitory lymphocytes and complement fixing ICA. The exact mechanism of the B cell inhibition in our test is not yet fully elucidated. Studies are currently underway to verify whether T lymphocytes are responsible for a cell-mediated cytotoxicity, but antibody dependent cytotoxicity cannot yet be excluded. The presence of definite islet cell damage (rather than functional inhibition) cannot be affirmed in the absence of morphological studies.
The high proportion of IDD patients with positive ICA and inhibitory lymphocytes, compared with that in other reports [2, 24] , is clearly explained by the fact that patients were not taken at random in our series. Seventeen patients were selected on the basis of an association with autoimmune manifestations. However, in subjects with recent-onset diabetes but no detectable autoimmune disease, we demonstrated the presence of leA (six cases out of six) and inhibitory lymphocytes (four cases out of six).
These findings may have important clinical and therapeutic implications in the understanding and management of some forms of diabetes.
